Latest CFTR Stories
BOULDER, Colo., Nov. 19, 2014 /PRNewswire/ -- N30 Pharmaceuticals, Inc.
NEW YORK, Oct.
LAUSANNE, Switzerland, October 1, 2014 /PRNewswire/ -- Sophia Genetics, the European leader in Clinical Genomics and Next Generation Sequencing (NGS) data analysis, today
New research report “Cystic Fibrosis Therapeutics in Major Developed Markets to 2019 - CFTR Modulators Initiate Drive towards Personalized Treatment and Market Growth” worked out by GBI Research
ALBANY, New York, February 18, 2014 /PRNewswire/ -- MarketResearchReports.Biz includes new market research report " Cystic Fibrosis Therapeutics In Major Developed Markets
ResearchMoz.us include new market research report "Cystic Fibrosis Therapeutics in Major Developed Markets to 2019" to its huge collection of research reports.
ChanTest is a world leader in drug safety and discovery, in areas particularly relevant to Cystic Fibrosis. Cleveland, OH (PRWEB) September 11, 2013
With over 1,900 mutations in the genes responsible for cystic fibrosis (CF), separating the harmful alterations from the benign ones has been a long, arduous undertaking for geneticists. Until now, that is.
A little more than a year after the FDA approved Kalydeco (Vx-770), the first drug of its kind to treat the underlying cause of cystic fibrosis, University of Missouri researchers believe they have found exactly how this drug works and how to improve its effectiveness in the future.
- A poem in which the author retracts something said in an earlier poem.